<DOC>
	<DOCNO>NCT00920361</DOCNO>
	<brief_summary>To evaluate dosage administration method , efficacy safety Puregon relationship background factor patient dose administration method . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Designated Drug Use Investigation 1 Follistim Injection ( Study P06130 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Patients underwent IVF Patients tumor ovary , breast , uterus , pituitary hypothalamus Pregnant possible pregnant woman , lactate woman Patients undiagnosed atypical vaginal bleeding Patients history hypersensitivity ingredient product . Patients ovarian cyst enlarge ovary , relate polycystic ovarian disease</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>